We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

63 hedge funds and large institutions have $180M invested in Xenon Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

64% more capital invested

Capital invested by funds: $110M → $180M (+$70.1M)

44% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 16

9% more funds holding

Funds holding: 58 → 63 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.26% less ownership

Funds ownership: 69.15% → 68.88% (-0.26%)

Holders
63
Holders Change
+5
Holders Change %
+8.62%
% of All Funds
1.36%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
8
Increased
23
Reduced
16
Closed
3
Calls
$10K
Puts
–
Net Calls
+$10K
Net Calls Change
+$4K

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$1.66M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.06M
3
Capital International Investors
Capital International Investors
California
+$1M
4
GIM
Granahan Investment Management
Massachusetts
+$921K
5
SCM
Stonepine Capital Management
Oregon
+$838K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$1.58M
2
Two Sigma Investments
Two Sigma Investments
New York
-$1.2M
3
Millennium Management
Millennium Management
New York
-$823K
4
JP Morgan Chase
JP Morgan Chase
New York
-$792K
5
Renaissance Technologies
Renaissance Technologies
New York
-$792K
Name Holding Trade Value Shares
Change 		Change in
Stake
USAA
26
United Services Automobile Association
Texas
$1M +$836K +98,639 New
JP Morgan Chase
27
JP Morgan Chase
New York
$979K -$792K -93,407 -49%
IPC
28
Invesco Private Capital
New York
$808K -$424K -50,000 -39%
BFM
29
Boothbay Fund Management
New York
$753K +$335K +39,480 +114%
SC
30
Scotia Capital
Ontario, Canada
$682K +$3.2K +378 +0.6%
AA
31
ALPS Advisors
Colorado
$619K +$26.9K +3,168 +5%
Two Sigma Investments
32
Two Sigma Investments
New York
$591K -$1.2M -142,112 -71%
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$580K +$4.17K +492 +0.9%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$565K -$641K -75,588 -58%
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$559K – – –
MCM
36
Moore Capital Management
New York
$508K – – –
Millennium Management
37
Millennium Management
New York
$491K -$823K -97,096 -67%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$377K +$7.63K +900 +2%
Squarepoint
39
Squarepoint
New York
$326K +$272K +32,127 New
NSEDCP
40
NJ State Employees Deferred Compensation Plan
New Jersey
$254K – – –
Northern Trust
41
Northern Trust
Illinois
$246K +$101K +11,956 +98%
State Street
42
State Street
Massachusetts
$210K -$5.29K -624 -3%
EWM
43
Elmwood Wealth Management
California
$190K – – –
O
44
OppenheimerFunds
New York
$173K -$75.7K -8,933 -34%
Geode Capital Management
45
Geode Capital Management
Massachusetts
$143K – – –
WG
46
Winton Group
United Kingdom
$132K +$110K +13,012 New
Goldman Sachs
47
Goldman Sachs
New York
$124K -$3.54K -417 -3%
PNC Financial Services Group
48
PNC Financial Services Group
Pennsylvania
$119K +$99.2K +11,700 New
Dimensional Fund Advisors
49
Dimensional Fund Advisors
Texas
$113K – – –
Bank of Montreal
50
Bank of Montreal
Ontario, Canada
$109K -$8.48K -1,000 -9%
1
2
3

XENE Hedge Fund Activity: Q1 2019 in Review

63 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2019, worth a combined $180M — up 64% from $110M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new XENE positions and 3 closed out — a net gain of 5 holders — while 23 added to existing stakes and 16 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $1.66M. The largest seller was Citadel Advisors, cutting an estimated $1.58M.

  • 63 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2019, up from 58 in Q4 2018.
  • Funds reported $180M of Xenon Pharmaceuticals stock for Q1 2019, up 64% quarter-over-quarter.
  • 8 funds opened new Xenon Pharmaceuticals positions in Q1 2019 and 3 closed out, a net change of +5 holders.
  • The largest Xenon Pharmaceuticals buyer in Q1 2019 was Eventide Asset Management, an estimated $1.66M added.
  • The largest Xenon Pharmaceuticals seller in Q1 2019 was Citadel Advisors, an estimated $1.58M sold.

Based on aggregated 13F filings for Q1 2019.